1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsAACR Hematologic Malignancies Research Fellowship is sponsored by American Association for Cancer Research (AACR). Fellowship supporting postdoctoral or clinical research fellows to conduct research projects focused on hematologic malignancies, including diffuse large B-cell lymphoma.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
AACR Hematologic Malignancies Research Fellowship | Grants | AACR Select "Patients / Caregivers / Public" or "Researchers / Professionals" to filter your results. To further refine your search, toggle appropriate sections on or off.
Patient / Caregivers / Public Researchers / Professionals AACR Hematologic Malignancies Research Fellowship The AACR Hematologic Malignancies Research Fellowship represents an effort to encourage and support a postdoctoral or clinical research fellow to conduct basic, translational, clinical, or population sciences research projects focused on hematologic malignancies.
Fellow, Hematology and Medical Oncology Memorial Sloan Kettering Cancer Center Investigating Chromatin-Based Mechanisms of B cell Epigenetic Plasticity and Lymphomagenesis Scientific Statement of Research Diffuse large B cell lymphomas (DLBCLs) arise from mature B cells that have acquired stem-like properties, enabling them to self-renew and adapt to therapeutic challenges, which can drive disease relapse.
The linker histone H1, mutated in up to 40% of DLBCLs, normally sequesters stem cell genes within compact chromatin. H1 loss of function mutations lead to the aberrant expression of these genes, enhancing the fitness and phenotypic plasticity of germinal center B cells, thereby promoting lymphomagenesis. H1 loss results in a striking gain of H3K36me2, a histone H3 modification mediated by NSD2 and associated with open chromatin.
Although the role of H3K36me2 is poorly defined, preliminary data suggest it is critical in the acquisition and maintenance of plasticity. Dr. Healton hypothesizes that H1 mutations drive stem-like plasticity through NSD2-mediated H3K36me2 and that therapeutic interference with this epigenetic axis will abrogate DLBCL plasticity, fitness, and relapse potential, substantially improving outcomes for these patients.
Dr. Healton received his undergraduate degree from Skidmore College where he graduated summa cum laude with highest honors, majoring in Chemistry with a minor in Music. He then obtained his medical and doctoral degrees from Albert Einstein College of Medicine, and studied the roles of linker histones in epigenetic regulation.
After completing a residency in Internal Medicine at NYU-Langone Hospital, he began a fellowship in Medical Oncology and Hematology at Memorial Sloan Kettering Cancer Center in 2023. He sees patients in the Lymphoma Division and is conducting research at Weill-Cornell. Acknowledgment of Support “I am deeply honored and grateful to receive the AACR Hematologic Malignancies Research Fellowship.
This award will support my research into epigenetic mechanisms of lymphomagenesis with the aim of ultimately improving outcomes for patients. ” block needs to be placed in the location where the link block will be displayed--> Independent Research Grants Research Training and Fellowships AACR Anna D. Barker Basic Cancer Research Fellowship
According to the current listing, eligibility includes: Postdoctoral or clinical research fellows. Confirm the full requirements in the official notice before applying.
AACR Hematologic Malignancies Research Fellowship is funded by American Association for Cancer Research (AACR). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
The Breast Cancer Research Foundation launched a $100 million venture philanthropy fund at CGI on September 22, 2026, seeded with $23 million and aiming at 20 to 30 companies. Here is what the structure actually means for investigators, for startups in the valley of death, and for every disease foundation now weighing the same move.
Read articleCDC-RFA-DP-27-0023 puts the National Breast and Cervical Cancer Early Detection Program, the National Comprehensive Cancer Control Program, and the National Program of Cancer Registries into a single competition closing February 5, 2027. Three statutorily separate eligibility pools, one application deadline, and an award count that maps onto the incumbent footprint. Here is how to read that.
Read articleCDMRP reissued the FY26 BCRP Breakthrough Award Levels 1 and 2 and the Clinical Research Extension Award on September 3, 2026, with a November 4 pre-application deadline and a November 18 full application deadline. Round one closed July 8. The arithmetic across both windows accounts for nearly the entire FY26 appropriation — which tells you what kind of second chance this is.
Read article